{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:05:15Z","timestamp":1793390715406,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071345"],"award-info":[{"award-number":["82071345"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23745","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T16:08:45Z","timestamp":1702656525000},"page":"e23745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Altered serum levels of cytokines in patients with myasthenia gravis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-4563","authenticated-orcid":false,"given":"Shu-Li","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yue","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Lu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-7099","authenticated-orcid":false,"given":"Xiao-Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Sheng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e23745_bib1","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.heliyon.2023.e23745_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0404.2005.00374.x","article-title":"Myasthenia gravis: clinical, immunological, and therapeutic advances","volume":"111","author":"Romi","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.heliyon.2023.e23745_bib3","volume":"vol. 20","author":"Billiau","year":"2009"},{"key":"10.1016\/j.heliyon.2023.e23745_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.heliyon.2023.e23745_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<543::AID-MUS2>3.0.CO;2-9","article-title":"Cytokines and the pathogenesis of myasthenia gravis","volume":"20","author":"Zhang","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.heliyon.2023.e23745_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2174\/1566524019666190827162615","article-title":"Effects of follicular helper T cells and inflammatory cytokines on myasthenia gravis","volume":"19","author":"Wang","year":"2019","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.heliyon.2023.e23745_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.622306","article-title":"The role of natural killer cells in autoimmune diseases","volume":"12","author":"Kucuksezer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ceb.2008.05.006","article-title":"The killer's kiss: the many functions of NK cell immunological synapses","volume":"20","author":"Krzewski","year":"2008","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib9","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.4049\/jimmunol.1701500","article-title":"Single degranulations in NK cells can mediate target cell killing","volume":"200","author":"Gwalani","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3908061","article-title":"The role of IL-17 and related cytokines in inflammatory autoimmune diseases","volume":"2017","author":"Kuwabara","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.heliyon.2023.e23745_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4236562","article-title":"Cytotoxic function and cytokine production of natural killer cells and natural killer T-like cells in systemic lupus erythematosis regulation with interleukin-15","volume":"2019","author":"Lin","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.heliyon.2023.e23745_bib12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/art.30313","article-title":"Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-\u03b3 production in patients with active disease","volume":"63","author":"Hervier","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.heliyon.2023.e23745_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/intimm\/dxq463","article-title":"Impaired IFN-\u03b3 production and proliferation of NK cells in multiple sclerosis","volume":"23","author":"L\u00fcnemann","year":"2011","journal-title":"Int. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107880","article-title":"Natural killer cells promote the differentiation of follicular helper T cells instead of inducing apoptosis in myasthenia gravis","volume":"98","author":"Liu","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2023.e23745_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2023.e23745_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-021-02298-6","article-title":"Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis via modulating both adaptive and innate immunity","volume":"18","author":"Zhang","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.heliyon.2023.e23745_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577634","article-title":"High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis","volume":"358","author":"Uzawa","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-014-0179-6","article-title":"IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis","volume":"3","author":"Maurer","year":"2015","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.heliyon.2023.e23745_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clineuro.2017.04.012","article-title":"Increased expression of P2X7 receptor in peripheral blood mononuclear cells correlates with clinical severity and serum levels of Th17-related cytokines in patients with myasthenia gravis","volume":"157","author":"Zhang","year":"2017","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.heliyon.2023.e23745_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cyto.2005.02.011","article-title":"Correlation between intracellular interferon-gamma (IFN-gamma) production by CD4+ and CD8+ lymphocytes and IFN-gamma gene polymorphism in patients with type 2 diabetes mellitus and latent autoimmune diabetes of adults (LADA)","volume":"31","author":"Tsiavou","year":"2005","journal-title":"Cytokine"},{"key":"10.1016\/j.heliyon.2023.e23745_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/1079990041535665","article-title":"Intracellular IFN-gamma production and IL-12 serum levels in latent autoimmune diabetes of adults (LADA) and in type 2 diabetes","volume":"24","author":"Tsiavou","year":"2004","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.heliyon.2023.e23745_bib27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","article-title":"IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation","volume":"23","author":"Liao","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","article-title":"Functional specialization of interleukin-17 family members","volume":"34","author":"Iwakura","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2023.e23745_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106130","article-title":"Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis","volume":"80","author":"Hu","year":"2020","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2023.e23745_bib30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ane.13549","article-title":"Comorbidities in older patients with myasthenia gravis - comparison between early- and late-onset disease","volume":"145","author":"Klimiec-Moskal","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.heliyon.2023.e23745_bib31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/db11-1213","article-title":"Central role for interleukin-2 in type 1 diabetes","volume":"61","author":"Hulme","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.heliyon.2023.e23745_bib32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","article-title":"Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation","volume":"26","author":"Laurence","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2023.e23745_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/jbcpp-2020-0272","article-title":"Role of interleukin-2 and interleukin-18 in newly diagnosed type 2 diabetes mellitus","volume":"33","author":"Suri","year":"2021","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib34","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1007\/s11033-021-06545-0","article-title":"Association of interleukin-2, interleukin-21 and interleukin-23 with hyperlipidemia in pediatric type 1 diabetes","volume":"48","author":"Khalil","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.heliyon.2023.e23745_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11892-014-0553-6","article-title":"Interleukin 2 in the pathogenesis and therapy of type 1 diabetes","volume":"14","author":"Rosenzwajg","year":"2014","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.heliyon.2023.e23745_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10072-013-1460-3","article-title":"Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis","volume":"35","author":"Li","year":"2014","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.heliyon.2023.e23745_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123546","article-title":"Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK","volume":"10","author":"Yilmaz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e23745_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12865-022-00501-8","article-title":"Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis","volume":"23","author":"Huan","year":"2022","journal-title":"BMC Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib39","article-title":"Clinical characteristics and prognosis of anti-AChR positive myasthenia gravis combined with anti-LRP4 or anti-titin antibody","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib40","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2010-08-299214","article-title":"The multifaceted granulysin","volume":"116","author":"Zitvogel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e23745_bib41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1399-0039.2008.01218.x","article-title":"Biology and clinical relevance of granulysin","volume":"73","author":"Krensky","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.heliyon.2023.e23745_bib42","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2010-03-273953","article-title":"Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin","volume":"116","author":"Tewary","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e23745_bib43","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.7510905","article-title":"Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule","volume":"263","author":"Cheng","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2023.e23745_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2249.1997.d01-901.x","article-title":"Serum levels of soluble Fas\/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases","volume":"107","author":"Jodo","year":"1997","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.heliyon.2023.e23745_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000375","article-title":"Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus","volume":"7","author":"Vincent","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.heliyon.2023.e23745_bib46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08820130601069715","article-title":"Serum CD40\/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response","volume":"36","author":"Mysliwiec","year":"2007","journal-title":"Immunol. Invest."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023109534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023109534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:29:54Z","timestamp":1790656194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023109534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023109534"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23745","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered serum levels of cytokines in patients with myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23745"}}